SERUM THYMIDINE KINASE AND VASCULAR EN DOTHELIAL GROWTH FACTOR (VEGF) IN RENAL CELL CARCINOMA

被引：0
|
作者：
Nisman, B. [1 ]
Nechushtan, H. [1 ]
Yutkin, V. [2 ]
Peretz, T. [1 ]
Gronowitz, S. [3 ]
Pode, D. [2 ]
机构：
[1] Hadassah & Hebrew Univ, Med Ctr, Dept Oncol, Jerusalem, Israel
[2] Hadassah & Hebrew Univ, Med Ctr, Dept Urol, Jerusalem, Israel
[3] Uppsala Univ, Grp Clin Virol, Dept Med Sci, Uppsala, Sweden
来源：
TUMOR BIOLOGY | 2010年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S64 / S65
页数：2
相关论文
共 50 条
  • [41] Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with carcinoma and sarcoma
    Linder, C
    Linder, S
    Munck-Wikland, E
    Strander, H
    ANTICANCER RESEARCH, 1998, 18 (3B) : 2063 - 2068
  • [42] VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) BACKFILTRATION IN THE RENAL GLOMERULUS
    Kuppe, Christoph
    Rohlfs, Wilko
    Grepl, Martin
    Schulte, Kevin
    Elger, Marlies
    Sanden, Silja
    Saritas, Turgay
    Andrae, Johanna
    Betsholtz, Christer
    Quaggin, Susan
    Trautwein, Christian
    Hausmann, Ralf
    Bachmann, Sebastian
    Kriz, Wilhelm
    Tufro, Alda
    Floege, Juergen
    Moeller, Marcus
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32
  • [43] The role of vascular endothelial growth factor (VEGF) in renal pathophysiology
    Schrijvers, BF
    Flyvbjerg, A
    De Vriese, AS
    KIDNEY INTERNATIONAL, 2004, 65 (06) : 2003 - 2017
  • [44] Hypertension and VEGF (Vascular Endothelial Growth Factor) Receptor Tyrosine Kinase Inhibition Effects on Renal Function
    Boursiquot, Brian C.
    Zabor, Emily C.
    Glezerman, Ilya G.
    Jaimes, Edgar A.
    HYPERTENSION, 2017, 70 (03) : 552 - 558
  • [45] Thymidine phosphorylase levels as a prognostic factor in renal cell carcinoma
    Wada, S
    Yoshimura, R
    Naganuma, T
    Yoshida, N
    Narita, K
    Ikemoto, S
    BJU INTERNATIONAL, 2003, 91 (01) : 105 - 108
  • [46] PHASE 2 CLINICAL EVALUATION OF PRECLINICALLY DEFINED BIOMARKERS FOR VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) TYROSINE KINASE INHIBITOR (TKI) TIVOZANIB IN RENAL CELL CARCINOMA (RCC)
    Hutson, T.
    Rathmell, W. K.
    Feng, B.
    Robinson, M. O.
    Gyuris, J.
    Lin, J.
    Choueiri, T.
    ANNALS OF ONCOLOGY, 2014, 25
  • [47] Everolimus for Korean patients with metastatic renal cell carcinoma who have failed initial treatment of a vascular endothelial growth factor (VEGF): Tyrosine kinase inhibitor (TKI).
    Park, Kwonoh
    Ahn, Jin-Hee
    Song, Cheryn
    Hong, Jun Hyuk
    Kim, Choung-Soo
    Ahn, Hanjong
    Lee, Jae-Lyun
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [48] Vascular Endothelial Growth Factor (VEGF) expression in prostate carcinoma
    Dema, A.
    Lazureanu, C.
    Anderco, D.
    Bardan, R.
    Bucuras, V.
    Cornea, R.
    Ursoniu, S.
    Taban, S.
    Cornianu, M.
    Muresan, A.
    VIRCHOWS ARCHIV, 2015, 467 : S270 - S270
  • [49] CORRELATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND Ki-67 EXPRESSION WITH HISTOLOGICAL GRADE AND STAGE OF RENAL CELL CARCINOMA
    Chakraborty, Bidisha
    Sarkar, Piyabi
    Bhattacharya, Palas
    Ghosh, Triparna
    Maiti, Krishnendu
    JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL SCIENCES-JEMDS, 2019, 8 (10): : 706 - 711
  • [50] Expression of vascular endothelial growth factor protein in human renal cell carcinoma
    Jacobsen, J
    Grankvist, K
    Rasmuson, T
    Bergh, A
    Landberg, G
    Ljungberg, B
    BJU INTERNATIONAL, 2004, 93 (03) : 297 - 302
12345